1411 POSTER Endpoints for Validation of Tumour Markers for Recurrence Risk -Recurrence-free Interval (RFI), Disease-free Survival (DFS), Overall Survival (OS), and Colon-cancer Specific Survival (CCSS) in CALGB 9581
Publication
, Conference
Mahmoud, NN; Lopatin, M; Clark-Langone, K; Lee, M; Niedzwiecki, D; Venook, AP
Published in: European Journal of Cancer
September 2011
Duke Scholars
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
September 2011
Volume
47
Start / End Page
S172 / S172
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Mahmoud, N. N., Lopatin, M., Clark-Langone, K., Lee, M., Niedzwiecki, D., & Venook, A. P. (2011). 1411 POSTER Endpoints for Validation of Tumour Markers for Recurrence Risk -Recurrence-free Interval (RFI), Disease-free Survival (DFS), Overall Survival (OS), and Colon-cancer Specific Survival (CCSS) in CALGB 9581. In European Journal of Cancer (Vol. 47, pp. S172–S172). Elsevier BV. https://doi.org/10.1016/s0959-8049(11)70904-2
Mahmoud, N. N., M. Lopatin, K. Clark-Langone, M. Lee, D. Niedzwiecki, and A. P. Venook. “1411 POSTER Endpoints for Validation of Tumour Markers for Recurrence Risk -Recurrence-free Interval (RFI), Disease-free Survival (DFS), Overall Survival (OS), and Colon-cancer Specific Survival (CCSS) in CALGB 9581.” In European Journal of Cancer, 47:S172–S172. Elsevier BV, 2011. https://doi.org/10.1016/s0959-8049(11)70904-2.
Mahmoud NN, Lopatin M, Clark-Langone K, Lee M, Niedzwiecki D, Venook AP. 1411 POSTER Endpoints for Validation of Tumour Markers for Recurrence Risk -Recurrence-free Interval (RFI), Disease-free Survival (DFS), Overall Survival (OS), and Colon-cancer Specific Survival (CCSS) in CALGB 9581. In: European Journal of Cancer. Elsevier BV; 2011. p. S172–S172.
Mahmoud, N. N., et al. “1411 POSTER Endpoints for Validation of Tumour Markers for Recurrence Risk -Recurrence-free Interval (RFI), Disease-free Survival (DFS), Overall Survival (OS), and Colon-cancer Specific Survival (CCSS) in CALGB 9581.” European Journal of Cancer, vol. 47, Elsevier BV, 2011, pp. S172–S172. Crossref, doi:10.1016/s0959-8049(11)70904-2.
Mahmoud NN, Lopatin M, Clark-Langone K, Lee M, Niedzwiecki D, Venook AP. 1411 POSTER Endpoints for Validation of Tumour Markers for Recurrence Risk -Recurrence-free Interval (RFI), Disease-free Survival (DFS), Overall Survival (OS), and Colon-cancer Specific Survival (CCSS) in CALGB 9581. European Journal of Cancer. Elsevier BV; 2011. p. S172–S172.
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
September 2011
Volume
47
Start / End Page
S172 / S172
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis